PRESCRIRE'S RATINGS
Our judgement is based on the therapeutic advance of the product in the relevant clinical situation. It considers not only the inherent value of each product in terms of its harm-benefit balance, but also its advantages and disadvantages relative to existing treatments. Note that the relative value of new products can vary from one country to another.
|
|
BRAVO
The product is a major therapeutic advance in an area where previously no treatment was available.
|
|
A REAL ADVANCE
The product is an important therapeutic advance but has certain limitations.
|
|
OFFERS AN ADVANTAGE
The product has some value but does not fundamentally change current therapeutic practice.
|
|
POSSIBLY HELPFUL
The product has minimal additional value, and should not change prescribing habits except in rare circumstances.
|
|
NOTHING NEW
The product is a new substance but with no evidence that it has more clinical value than other substances of the same group. It can be a me-too or a near me-too.
|
|
NOT ACCEPTABLE
Product without evident benefit but with potential or real disadvantages.
|
|
JUDGEMENT RESERVED
The editors postpone their rating until better data and a more thorough evaluation of the product are available.
|
> The Prescrire Drug Awards for 2022
Download the full article:
FREE "The Prescrire Awards for 2022" Prescrire International 2023; 32 (246): 80-81. (pdf, free)
Back to "The Prescrire Awards for 2022">
©Prescrire March 2023
|
Share |
|
|
Enjoy full access to Prescrire International, and support independent analysis
|